Fibrx Therapeutics

Fibrx Therapeutics is a biotechnology company focused on developing transformative therapies for fibrotic diseases by modulating the extracellular matrix (ECM). The company's core technology centers on the localized regulation of Transforming Growth Factor-beta (TGF-beta) activation, a key driver of pathological scarring and tissue stiffening. Unlike systemic TGF-beta inhibitors that often face toxicity challenges, Fibrx's approach targets the latent complex of the cytokine as it is stored within the ECM. This allows for tissue-specific intervention, potentially providing a safer and more effective treatment profile. The company is currently advancing a pipeline of monoclonal antibodies for indications including hypertrophic scarring and systemic sclerosis.